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Sporotrichosis is an infection caused by a dimorphic fungus of the Sporothrix schenckii complex. Host immunity is an
important factor in the clinical manifestations of the disease. Deeply immunocompromised individuals, especially
those infected with the Human Immunodeficiency Virus (HIV) and T CD4 counts < 350 cells/ul lymphocytes, may
present with the systemic form of sporotrichosis. This report describes a case of disseminated sporotrichosis caused
by S. brasiliensis in a patient with advanced AIDS. The skin, lungs, bones and central nervous system were affected.
Medical treatment involved the administration of amphotericin B, terbinafine, itraconazole and posaconazole.
Posaconazole was associated with the best clinical response and clearing of the fungus from the central nervous
system.
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Sporotrichosis may be an acute or chronic infection caused
by a dimorphic fungus of the Sporothrix schenckii complex
[1] generally located in cutaneous and sub-cutaneous tissue,
often associated with lymphatic involvement. The fungus
can disseminate to bones, lungs and central nervous
system, especially in immunosuppressed patients [2-6].
Recent publications have drawn attention to the possibility
of dissemination related to fungal virulence factors, as is
the case for S. brasiliensis [7].
The disease usually manifests as isolated cases or out-
breaks related to specific occupational exposure; how-
ever, recently, it has reached epidemic proportions in
some parts of Latin America, India [8] and Northeastern
China [9]. The clinical, demographic and epidemiologic
features vary within regions. The disease affects predom-
inantly tropical and subtropical regions, being the most
prevalent subcutaneous mycosis in South America. In
Brazil, it is the most common cutaneous mycosis, and,
in the Rio de Janeiro metropolitan area, it has been* Correspondence: aricapaixao@hotmail.com; cristianelamas@gmail.com
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unless otherwise stated.considered an epidemic zoonosis since the 1990s [2]. In
this area, sporotrichosis occurs mostly via transmission
from infected cats to humans, and genotypic analysis
has shown that samples isolated from the Rio de Janeiro
epidemic have a high genetic similarity. This finding is
suggestive of a common niche, as S. brasiliensis is the
species most frequently found in the city and in its sur-
roundings [2,7]. Currently, this species is considered the
most virulent of the Sporothrix schenckii complex [10].
On the other hand, the immune system of the host is an
important factor that contributes to the different forms
of the disease [11-14]. HIV co-infection clearly modifies
the clinical consequences of the disease because T CD4
lymphocytes play an important role in the control of this
mycosis. HIV infection aggravates sporotrichosis, with a
higher incidence of severe disseminated cases and a
higher number of hospitalizations and deaths [15]. The
classical presentation of sporotrichosis is polymorphic
lesions in the skin and sub-cutaneous tissue, comprom-
ising the adjoining lymphatics. The most affected cuta-
neous sites are those where the skin is most exposed to
the environment. The incubation period is on average
three weeks from the inoculation date.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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form, followed by the cutaneous form and the disseminated
form. This report details a case of disseminated sporotri-
chosis in an HIV-positive female patient with advanced
HIV immunosuppression.
Clinical case
LSC, a 20- year- old female from Campos dos Goytacases
(41°19’28”W), a city in the rural part of the state of Rio de
Janeiro ( 274 km from Rio de Janeiro city), was diagnosed
HIV positive in March 2011. She was a student and single.
Due to the lack of laboratory resources in the patient’s
hometown, CD4 and viral load were not collected at the
time of diagnosis, and zidovudine (AZT), lamivudine, lopi-
navir and ritonavir were prescribed six months later due to
progressive weight loss and fatigue.
On January 2012, the patient was scratched by her cat
on the left hand, where the first polymorphic lesions
(vegetative, nodular, ulcerous and crusty) appeared on
the skin, spreading afterwards. Because of the severe skin
condition, the patient was admitted on April 2012 to the
Ferreira Machado Hospital in Campos dos Goytacases
where she received deoxycholate amphotericin B (AMB)
and itraconazole 600 mg/day, in addition to the anti-
retroviral therapy. A total dose dose of 2,05 g AMB was
given along the 45 days of hospitalization. She showed
no improvement in her condition and was therefore
transferred to a referral Infectious Diseases hospital.
On June 2012, the patient was transferred to the Institute
of Clinical Research (ICR) Evandro Chagas/FIOCRUZ
(IPEC) due to the difficulty in managing the spreading
polymorphic skin lesions associated with a wasting syn-
drome, severe protein-caloric malnutrition and the worsen-
ing of her general condition (Figure 1A, B).
Initial exams at the ICR showed macrocytic anemia
(hemoglobin 10,3 g/dl; hematocrit 31,1%, MCV 105);
leukocytosis 18110 mm3 with 10% band forms; C react-
ive protein of 32.48 mg/dl (reference level < 0.5), CD4
111 cells/mm3 (11,65%); CD8 605 cells/mm3 (63,75%);
and a viral load of 92 copies/mm3. Cultures from blood,Figure 1 Photographs on admission to IPEC/FIOCRUZ on June,
2012. Polymorphic Sporotrichosis Lesions.cerebrospinal fluid (CSF), induced sputum, urine and se-
cretions from skin lesions were performed using Sabour-
aud, Mycosel and BHI-Agar and resulted positive for
Sporothrix spp. A subsequent partial sequencing of the cal-
modulin gene showed that the isolate was actually S. brasi-
liensis. Plain radiographs and computed tomography (CT)
scans showed osteolytic lesions, possibly due to fungal inva-
sion. A bone biopsy was not performed because there was
no local facility available for this type of procedure; more-
over, given the results of all other exams, the biopsy was
considered to be invasive and unnecessary (Figure 2A, B).
At first, treatment with amphotericin B deoxycholate
(1 mg/Kg/day; patient’s weight was 45 Kg) was maintained,
and later on, it was substituted for a liposomal formulation.
On July 16, 2012, treatment with itraconazole 200 mg/day
was resumed and terbinafine 250 mg/day was associated.
The patient had been taking zidovudine, lamivudine, lopi-
navir and ritonavir, but AZT was changed to abacavir due
to severe anemia detected on August 2012. Skin lesions im-
proved slowly and gradually, probably as a result of the
antifungal and antiretroviral treatment and the weekly
sessions of cryotherapy, which went on for 18 months
(Figure 3A, B, C, D). The patient also presented an im-
provement in general condition with a weight gain of 6
Kg. She was able to stand and walk with assistance fol-
lowing weeks of intensive physiotherapy.
However, even with the general improvement and
triple antifungal therapy with liposomal AMB, itracona-
zole and terbinafine, S. brasiliensis still grew in CSF that
was collected up to October 2012, despite the fact the
patient had no neurological symptoms. Because of the
difficulty in sterilizing the CSF, on September 2012, ter-
binafine and itraconazole were stopped and posacona-
zole was prescribed at the dose of 800 mg/day [16,17],
still associated with deoxycholate AMB. The administra-
tion of posaconazole was continuous but the AMB was
not, as deep intravenous access was difficult and increases
in serum creatinine occurred. The fungal susceptibility test-
ing (Additional file 1) was done with the M38A2 method
and CLSI 2008 standards on the S. brasiliensis isolated
from the skin, sputum and CSF. The test results showed
good sensitivity to terbinafine and voriconazole, intermedi-
ate sensitivity to AMB, and low sensitivity to itraconazole
and ketoconazole. Posaconazole was not tested because
there were no cut offs defined for this fungus; instead, its
sensitivity was determined by comparing it to previous re-
ports of S. brasiliensis isolates [18].
Mycological surveillance was performed monthly, and
the first sterile CSF was seen on November 2012, a
month after starting treatment with posaconazole. CSF
sterility was documented until October 2013, despite the
progressive cytological and biochemical changes seen in
CSF (Additional file 1). The inflammatory changes led to
the suspicion of meningeal tuberculosis or immune
Figure 2 Plain radiographs of hands (A) and lower limbs (B) showing osteolytic lesions (on June 2012, admission to IPEC).
Paixão et al. AIDS Research and Therapy  (2015) 12:16 Page 3 of 6reconstitution syndrome, and empirical therapy with
rifampin, isoniazid, pyrazinamide and ethambutol was
given for 28 days and associated with dexamethasone
(8 mg IV tds) for 14 days. At this point, the patient
presented a CD4 cell count of 304 (11%) and a viral
load < 40 copies/ml (Additional file 1).June 2012
June 2012
Figure 3 Evolution of the skin lesions after treatment. Evolution of theDuring October 2013, the patient presented confusion,
headache and nystagmus. Repeat brain CT scans showed
exudative hydrocephalus, hypodensity of the white sub-
stance adjacent to the lateral ventricles, compatible with
cerebrospinal fluid transudation, cortical sulci deletion and
intense meningeal enhancement (Figure 4). Concurrently, July 2013
September 2013
skin lesions.
Figure 4 Brain CT Scan on October 2013 showing exudative hydrocephalus.
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liensis. The patient was given a ventriculoperitoneal shunt
(VPS) at the Bonsucesso General Hospital on October 22,
2013, with significant improvement of the neurological sta-
tus. Approximately two months after placement of the
CSF shunt, the patient once again presented with the
same neurological symptoms and signs: CT scans
showed recurrence of the hydrocephalus (Figure 5A, B)
and an organized intrahepatic CSF collection, which in-
dicated obstruction of the shunt (Figure 6A, B). On
January 2014, the patient was given a new shunt re-
placement, and a few hours after the procedure, she
passed away from an undetermined cause.
Discussion
A severe case of S. brasiliensis disseminated sporotri-
chosis in a young female HIV-positive patient from Rio
de Janeiro State in Brazil is presented. The severity of
the case is shown by the isolation of the strain S. brasi-
liensis from cultures of the skin, sputum, blood and
central nervous system, and the probable fungal osteo-
myelitis present radiologically. Virulence studies in aFigure 5 Brain CT scan on January 2014, showing intraventricular shumouse infection model have shown that S. brasiliensis
is significantly more lethal and results in higher fungal
burdens compared to S. schenckii as well as other ex-
amined Sporothrix spp. Recently this species was also
associated to aggressive and atypical cases [10,19].
Severity was also related to the poor clinical and
mycological response to itraconazole and amphotericin
B (the latter in high dose) during many months. Al-
though itraconazole has been shown to treat S. schenkii
complex adequately in a cohort of patients from the Rio
de Janeiro metropolitan area [20], the strain isolated
from our patient was itraconazole resistant. This finding
raises the point that the itraconazole resistance found
over time in strains in Rio de Janeiro could be related to
the use of itraconazole to treat sick cats, which are the
main source of S. brasiliensis. In this specific case, the
patient had received itraconazole for 45 days at the time
the first isolates were submitted for fungal sensitivity
testing, which results showed itraconazole resistance.
The use of a combination of antifungals has not been de-
scribed for treating sporotrichosis; however, for other my-
cosis such as chromoblastomycosis, this combination hasnt in place and hydrocephalus.
Figure 6 Abdomen CT Scan, January 2014, showing infrahepatic fluid collection (CSF).
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with the combination of terbinafine and itraconazole
against one isolate of C. carrionii, and no antagonism was
observed when amphotericin B was combined with terbina-
fine or itraconazole against agents of chromoblastomycosis
[21]. Weekly cryotherapy sessions occurred for a long
period and resulted in the improvement of infiltrated cuta-
neous lesions, therefore favoring the skin penetration by
antifungal agents.
Posaconazole is a modern azole and was chosen based
on its good sensitivity profile to S. schenckii (and re-
cently to S. brasiliensis) and its good penetration in bone
and in the central nervous system [22,23]. Posaconazole
showed both in vitro and in vivo action against a wide
variety of fungi, including the rare and resistant ones.
Several case reports describe success in the treatment of
refractory fungal diseases or in patients who are unable
to tolerate other drugs. Additionally, posaconazole can
be given orally and is well tolerated [16]. Although the
profile of voriconazole susceptibility in our isolates
pointed us to a good sensitivity, based on previous stud-
ies that showed high MIC values in S. schenckii, associ-
ated with a lack of clinical studies, we decided not to use
it, preferring posaconazole. In the present report, the
use of posaconazole for two months coincided with fun-
gal clearance from bi-monthly CSF cultures and a sus-
tained response for 10 months.
It is not clear why the patient relapsed. It may be that
posaconazole absorption was erratic, as has been sug-
gested in other reports [24], and levels in CSF may have
not been sufficient to suppress fungal growth. Alterna-
tively, the isolate may have become resistant. These
seem to be the most likely reasons because immune re-
sponse had significantly improved at the time relapse
occurred.
This case illustrates how serious sporotrichosis-HIV
coinfection is and the need for frequent mycologicalsurveillance, especially in cases where the central ner-
vous system is involved. Also S. brasiliensis may present
resistance to antifungals and is a virulent species.Conclusions
S. brasiliensis sporotrichosis and HIV coinfection is a
serious condition. Treatment is an unresolved issue, but
posaconazole seems to be an effective drug. There is
need for frequent mycological surveillance, especially in
cases where the central nervous system is involved.
More studies are needed in order to confirm the benefit
of posaconazole treatment in S. brasiliensis infections.Consent
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